<code id='853D6E1911'></code><style id='853D6E1911'></style>
    • <acronym id='853D6E1911'></acronym>
      <center id='853D6E1911'><center id='853D6E1911'><tfoot id='853D6E1911'></tfoot></center><abbr id='853D6E1911'><dir id='853D6E1911'><tfoot id='853D6E1911'></tfoot><noframes id='853D6E1911'>

    • <optgroup id='853D6E1911'><strike id='853D6E1911'><sup id='853D6E1911'></sup></strike><code id='853D6E1911'></code></optgroup>
        1. <b id='853D6E1911'><label id='853D6E1911'><select id='853D6E1911'><dt id='853D6E1911'><span id='853D6E1911'></span></dt></select></label></b><u id='853D6E1911'></u>
          <i id='853D6E1911'><strike id='853D6E1911'><tt id='853D6E1911'><pre id='853D6E1911'></pre></tt></strike></i>

          hotspot

          hotspot

          author:knowledge    Page View:78
          Cambridge: AbbVie
          The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 — nearly a million dollars more than the company has ever spent in a single quarter. Ruby Wallau for STAT

          WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 alone — more than any other drugmaker spent in the same period, and nearly a million dollars more than the company spent in the same period last year.

          AbbVie was the seventh-highest corporate lobbying spender last quarter, ahead of giants like Lockheed Martin, CVS Health, and, AT&T, federal records show.

          advertisement

          The number is eye-popping even for the pharmaceutical industry, which is known for its omnipresence on Capitol Hill, and its nearly unlimited lobbying budgets.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Changes to biosimilar regulatory framework must prioritize patients
          Changes to biosimilar regulatory framework must prioritize patients

          JUANMABROMATA/AFPviaGettyImagesBiosimilarsarenolongeranewanduntestedclassofmedicines.Today,theyprovi

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Abridge raises $150m as clinical notes automation market heats up

          AdobeAPittsburghartificialintelligencestartupemergingasachallengertoMicrosoft’sclinicalnotetakingbus